RecruitingNot ApplicableNCT06127056

Intervention Effect of High-Definition Transcranial Alternating Current Stimulation (HD-tACS) on Non-suicidal Self-injury (NSSI)


Sponsor

Anhui Medical University

Enrollment

40 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

To investigate the intervention effect of high-definition transcranial alternating current stimulation (HD-tACS) on patients with Non-suicidal Self-injury (NSSI) and its underlying neural mechanism by magnetic resonance imaging (MRI).


Eligibility

Min Age: 12 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called High-Definition Transcranial Alternating Current Stimulation (HD-tACS) and a medical device called sham High-Definition Transcranial Alternating Current Stimulation (HD-tACS) for people with non suicidal self injury and transcranial alternating current stimulation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHigh-Definition Transcranial Alternating Current Stimulation (HD-tACS)

tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

DEVICEsham High-Definition Transcranial Alternating Current Stimulation (HD-tACS)

In the sham condition, tACS was delivered only during the ramp-up and ramp-down periods (15s and 15s); no current was delivered during the 20-minute intervention.


Locations(1)

Anhui Medical University

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06127056


Related Trials